These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 2966742)

  • 1. The effect of the thromboxane receptor antagonist BM 13.177 on experimentally induced coronary artery thrombosis in the pig.
    van der Giessen WJ; Zijlstra FJ; Berk L; Verdouw PD
    Eur J Pharmacol; 1988 Mar; 147(2):241-8. PubMed ID: 2966742
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparative evaluation of thromboxane receptor blockade, thromboxane synthase inhibition and both in animal models of arterial thrombosis.
    Salvati P; Dho L; Ukmar G; Vaga L; Rimoldi O; Patrono C
    J Pharmacol Exp Ther; 1994 Apr; 269(1):238-45. PubMed ID: 8169831
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Beneficial effects of combined thromboxane synthase inhibition/receptor blockade with CGS 22652 in a canine model of coronary thrombosis.
    Olson RW; Dotson R; Mathis J; Cohen DS; Webb RL
    Eur J Pharmacol; 1993 May; 236(1):75-87. PubMed ID: 8319746
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination of the thromboxane receptor antagonist, sulotroban (BM 13.177; SK&F 95587), with streptokinase: demonstration of thrombolytic synergy.
    Kopia GA; Kopaciewicz LJ; Ohlstein EH; Horohonich S; Storer BL; Shebuski RJ
    J Pharmacol Exp Ther; 1989 Sep; 250(3):887-95. PubMed ID: 2528630
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of BM-573 [N-terbutyl-N'-[2-(4'-methylphenylamino)-5-nitro-benzenesulfonyl]urea], a dual thromboxane synthase inhibitor and thromboxane receptor antagonist, in a porcine model of acute pulmonary embolism.
    Ghuysen A; Lambermont B; Dogné JM; Kolh P; Tchana-Sato V; Morimont P; Magis D; Hanson J; Segers P; D'Orio V
    J Pharmacol Exp Ther; 2004 Sep; 310(3):964-72. PubMed ID: 15121765
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of selective endoperoxide/thromboxane A2 receptor antagonism with sulotroban on tPA-induced thrombolysis in a rabbit model of femoral arterial thrombosis.
    Fujita T; Hasan S; Storer BL; Shebuski RJ
    Fundam Clin Pharmacol; 1989; 3(6):643-53. PubMed ID: 2533138
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduction of in vivo coronary artery thrombosis by the novel thromboxane antagonist (3R)-3-(4-fluorophenylsulfonamido)-1,2,3,4-tetrahydro-9- carbazolepropanoic acid.
    Fiedler VB; Perzborn E; Seuter F; Rosentreter U; Böshagen H
    Arzneimittelforschung; 1989 Dec; 39(12):1527-30. PubMed ID: 2624600
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of aspirin on local prostaglandin production and serotonin accumulation in a canine model with coronary cyclic flow variations or thrombosis.
    Yao SK; Benedict CR; Rosolowsky M; McNatt J; Falinska B; Campbell WB; Buja LM; Willerson JT
    J Mol Cell Cardiol; 1991 Apr; 23(4):473-82. PubMed ID: 1942081
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BM-573, a dual thromboxane synthase inhibitor and thromboxane receptor antagonist, prevents pig myocardial infarction induced by coronary thrombosis.
    Rolin S; Petein M; Tchana-Sato V; Dogne JM; Benoit P; Lambermont B; Ghuysen A; Kolh P; Masereel B
    J Pharmacol Exp Ther; 2003 Jul; 306(1):59-65. PubMed ID: 12721335
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacological characterization of FCE 27262, a combined thromboxane synthase inhibitor and PGH2/TXA2 receptor antagonist.
    Vaghi F; Colombo M; Pierucci L; Volpi D; Dho L; Ukmar G; Rosa B; Salvati P
    Drugs Exp Clin Res; 1993; 19(6):249-60. PubMed ID: 8013268
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Endogenous prostaglandin endoperoxides and prostacyclin modulate the thrombolytic activity of tissue plasminogen activator. Effects of simultaneous inhibition of thromboxane A2 synthase and blockade of thromboxane A2/prostaglandin H2 receptors in a canine model of coronary thrombosis.
    Golino P; Rosolowsky M; Yao SK; McNatt J; De Clerck F; Buja LM; Willerson JT
    J Clin Invest; 1990 Oct; 86(4):1095-102. PubMed ID: 2145320
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of acute myocardial ischaemia with a selective antagonist of thromboxane receptors (BM 13.177).
    Schrör K; Thiemermann C
    Br J Pharmacol; 1986 Apr; 87(4):631-7. PubMed ID: 3011166
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Beneficial actions of thromboxane receptor antagonism in hemorrhagic shock.
    Bitterman H; Yanagisawa A; Lefer AM
    Circ Shock; 1986; 20(1):1-11. PubMed ID: 2945667
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of ONO-3708, an antagonist of the thromboxane A2/prostaglandin endoperoxide receptor, on platelet aggregation and thrombosis.
    Kondo K; Seo R; Naka M; Kitagawa T; Wakitani K; Sakata M; Kira H; Okegawa T; Kawasaki A
    Eur J Pharmacol; 1989 Apr; 163(2-3):253-61. PubMed ID: 2721574
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protective effects of a new specific thromboxane antagonist in arachidonate-induced sudden death.
    Lefer DJ; Mentley RK; Lefer AM
    Arch Int Pharmacodyn Ther; 1987 May; 287(1):89-95. PubMed ID: 2957969
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prostaglandin D2 interacts at thromboxane receptor-sites on guinea-pig platelets.
    Hamid-Bloomfield S; Whittle BJ
    Br J Pharmacol; 1986 Aug; 88(4):931-6. PubMed ID: 3017497
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protamine-heparin-induced pulmonary hypertension in pigs: effects of treatment with a thromboxane receptor antagonist on hemodynamics and coagulation.
    Nuttall GA; Murray MJ; Bowie EJ
    Anesthesiology; 1991 Jan; 74(1):138-45. PubMed ID: 1824742
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro and in vivo pharmacological characterization of BM-613 [N-n-pentyl-N'-[2-(4'-methylphenylamino)-5-nitrobenzenesulfonyl]urea], a novel dual thromboxane synthase inhibitor and thromboxane receptor antagonist.
    Hanson J; Rolin S; Reynaud D; Qiao N; Kelley LP; Reid HM; Valentin F; Tippins J; Kinsella BT; Masereel B; Pace-Asciak C; Pirotte B; Dogné JM
    J Pharmacol Exp Ther; 2005 Apr; 313(1):293-301. PubMed ID: 15626721
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of selective endoperoxide/thromboxane A2 receptor antagonism with sulotroban on lysis time and reocclusion rate after tissue plasminogen activator-induced coronary thrombolysis in the dog.
    Shebuski RJ; Smith JM; Storer BL; Granett JR; Bugelski PJ
    J Pharmacol Exp Ther; 1988 Aug; 246(2):790-6. PubMed ID: 3136245
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential involvement of serotonin 2A/C and thromboxane A2/prostanoid receptors in high- vs. low-shear rate arterial thrombosis in rabbits.
    Valentin JP; Vieu S; Bertolino F; Fauré P; John GW
    J Pharmacol Exp Ther; 1997 Feb; 280(2):761-9. PubMed ID: 9023289
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.